Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

dition, Anesiva is pursuing corporate partnerships for the registration and commercialization of Zingo outside the licensed territories, and in support of the development and commercialization of Adlea for multiple potential indications.

Conference Call Details

Anesiva will conduct a webcast conference call with the investment community at 4:30 p.m. EDT, today, February 11, 2008 to discuss its financial results and to review the company's progress and future outlook. Interested parties can listen to the live conference call by dialing 800-340-6289 (international dial: 706-634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, a
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... July 31 InNexus,Biotechnology Inc., (TSX VENTURE: ... a drug development company commercializing the,next generation ... Cross Linking,(DXL(TM)) technology, will present at IBC,s ... of Innovative Therapeutics (DDT) Conference being,held in ...
... BERKELEY HEIGHTS, N.J., July 31 Genta,Incorporated (OTC ... release its second quarter 2008 financial results on ... conference call and live audio,webcast to discuss these ... Participants can access the live call by ...
... Amicus Therapeutics,(Nasdaq: FOLD ), a biopharmaceutical company ... of human,genetic diseases, will announce second quarter 2008 ... Thursday, August 7, 2008. The results,announcement will be ... that,afternoon at 5 p.m. EDT., Interested participants ...
Cached Biology Technology:InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 3Amicus Therapeutics Announces Second Quarter 2008 Results Release Date 2
(Date:7/11/2014)... American Society for Bone and Mineral Research awarded Michael ... Medicine (BUSM), with the 2014 Louis V. Avioli Award. ... BUSM, is internationally known for revolutionizing the understanding of ... , The award honors a member of the American ... contributions to bone and mineral basic research. It is ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... that remains unusually stable in the body, researchers at ... to the development of therapeutic RNA nanotechnology. Peixuan ... and professor of biomedical engineering, and his colleagues in ... construction of a thermodynamically stable RNA nanoparticle online in ...
... it turns out, suppresses melatonin 5 times more than exposure ... off an orange-yellow light. "Just as there are regulations and ... rules for the pollution stemming from artificial light at night," ... "White" light bulbs that emit light at shorter wavelengths ...
... Findings, published today in Nature and ... Pressure Genome-Wide Association Studies represent a major advance in our ... new potential therapeutic targets for prevention of heart disease and ... Research published in Nature and co-led by scientists ...
Cached Biology News:Team finds stable RNA nano-scaffold within virus core 2Dangers of exposure to 'white' light 2Dangers of exposure to 'white' light 3Discovery of blood pressure genes could help prevent cardiovascular disease 2Discovery of blood pressure genes could help prevent cardiovascular disease 3
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
NORMAL DONOR DONKEY SERUM...
... Molecular Probes Fc OxyBURST Green reagent (F-2902) ... of Boston University to permit measurement of ... and the subsequent oxidative burst directly in ... reagent consists of bovine serum albumin (BSA) ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: